ADC Therapeutics SA Stock-Based Compensation
ADC Therapeutics SA (ADCT) reported Stock-Based Compensation of $6.99 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- ADC Therapeutics SA share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $4.55M, a 151.24% increase year-over-year.
- ADC Therapeutics SA share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $2.44M, a 0.87% increase year-over-year.
- ADC Therapeutics SA share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $673.00K, a 58.35% decline year-over-year.
- ADC Therapeutics SA share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $2.00M, a 28.72% decline year-over-year.
- ADC Therapeutics SA share-based payment arrangement, noncash expense for fiscal 2025 was $6.91M, a 5.13% increase from fiscal 2024.
- ADC Therapeutics SA share-based payment arrangement, noncash expense for fiscal 2024 was $6.57M, a 51.33% decline from fiscal 2023.
- ADC Therapeutics SA share-based payment arrangement, noncash expense for fiscal 2023 was $13.49M, a 72.64% decline from fiscal 2022.
- ADC Therapeutics SA share-based payment arrangement, noncash expense for fiscal 2022 was $49.32M.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $6.99M 10-Q · filed 2026-08-13 | $7.67M derived: sum of 3 quarters · filed 2026-08-13 | $9.66M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.44M 10-Q · filed 2026-05-04 | $3.12M derived: sum of 2 quarters · filed 2026-05-04 | $5.12M derived: sum of 3 quarters · filed 2026-05-04 | $6.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $673.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $2.67M derived: sum of 2 quarters · filed 2026-03-10 | $4.48M derived: sum of 3 quarters · filed 2026-08-13 | $6.91M 10-K · filed 2026-03-10 |
| 2025-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.81M derived: sum of 2 quarters · filed 2026-08-13 | $6.23M 10-Q · filed 2025-11-10 | $7.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $1.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $4.23M 10-Q · filed 2026-08-13 | $5.85M derived: sum of 3 quarters · filed 2026-08-13 | $8.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $2.42M 10-Q · filed 2026-05-04 | $4.04M derived: sum of 2 quarters · filed 2026-05-04 | $6.84M derived: sum of 3 quarters · filed 2026-05-04 | $8.83M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $4.42M derived: sum of 2 quarters · filed 2026-03-10 | $6.41M derived: sum of 3 quarters · filed 2026-03-10 | $6.57M 10-K · filed 2026-03-10 |
| 2024-09-30 | $2.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.79M derived: sum of 2 quarters · filed 2025-11-10 | $4.95M 10-Q · filed 2025-11-10 | $7.17M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $1.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $2.15M 10-Q · filed 2025-08-12 | $4.37M derived: sum of 3 quarters · filed 2025-08-12 | $6.45M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $158.00K 10-Q · filed 2025-05-14 | $2.38M derived: sum of 2 quarters · filed 2025-05-14 | $4.46M derived: sum of 3 quarters · filed 2025-05-14 | $5.58M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $2.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $4.30M derived: sum of 2 quarters · filed 2025-03-27 | $5.42M derived: sum of 3 quarters · filed 2025-03-27 | $13.49M 10-K · filed 2025-03-27 |
| 2023-09-30 | $2.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $3.20M derived: sum of 2 quarters · filed 2024-11-07 | $11.28M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $9.19M 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $8.07M 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $49.32M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |